Missed Sonova's Run? What Holders Had To Believe

Sonova has been busy on the product front, rolling out AI powered hearing care tools like the Roger On Sphere microphone and new Integro sound processors for cochlear implants. Investors who held Sonova from the start of the year are up 41.7%, including dividends. If you were deciding back on 1 January whether to buy, what would you have needed to believe about competition, pricing power and clinic economics before any of this news hit the tape?

The move put Sonova in the middle of this trade. Scan 126 healthcare AI stocks for other companies exposed to it.

The Argument You Would Have Been Weighing Up On Sonova

The shares cost CHF207 at the start of the period, which already baked in a strong track record for Sonova and a rich set of expectations either way.

The bullish narrative pointed to a fair value of CHF260, a rough guide to what that upside scenario might justify, built on successful launches like Infinio and Sphere, plus tighter cost control that could lift net margins.

The bearish view anchored on a fair value of CHF189, reflecting worries that low-cost and over-the-counter rivals, plus weaker clinic profitability, would steadily chip away at Sonova's premium pricing power.

What The Evidence Did To The Sonova Argument

Sonova’s launch of AI powered hearing care products like Roger On Sphere and Integro supported the view that product refreshes could help sustain pricing and clinic relevance. The reported figures, however, pointed the other way on profitability. Total revenue moved from CHF3,612.9m in H2 2025 to CHF3,605.9m in H2 2026, while net income declined and net margin slipped from 15.5% to 14.9%. The evidence cut both ways.

The key issue here was the belief about pricing power and clinic economics. For a different stock with a similar story, it can be useful to track whether new products appear in higher average selling prices or at least stable margins in the reported segments, rather than only featuring in launch headlines.

What Sonova’s Run Up To CHF288 Already Prices In

Sonova shares now trade at CHF288 from CHF207 at the start of the year, and this selected Narrative’s Fair Value sits below that market price. The argument is less about AI headlines and more about whether slower hearing care market growth and FX pressure cap how much those tools can contribute.

The core question for you is what has to keep going right for CHF288 to hold up. A buyer today would need to believe AI hearing instruments, APAC expansion and cost savings can consistently offset softer market growth, elongated replacement cycles and currency headwinds.

"Although Sonova Holding points to AI-based platforms like Sphere and Ultra as long-term drivers of product appeal, the reset of underlying hearing care market growth expectations to 2 to 4% in FY26/27 with only gradual normalization toward 3 to 5% raises the risk that richer feature sets fail to translate into enough incremental volume or pricing to prevent slower reported revenue growth and softer earnings."

One Narrative disagrees with today's price. → See where this Narrative says Sonova should trade

Go Straight To The Source

What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.

• Company 1 - 17% below our estimate - shifts its mix toward higher margin prepared and packaged foods to deepen pricing power.
• Company 2 - 50% below our estimate - uses an AI powered revenue cycle platform as hospitals consolidate billing tools and workflows.
• Company 3 - 32% below our estimate - supplies liquid cooling and power systems required for efficient high density AI data centers.

Those are three of them. See the full list of 222 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com